Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Austria Clinical Trials

Preview: EASL 2015, what's left to say in hepatitis C?

This article was originally published in Scrip

Executive Summary

Analysts are expecting much less jubilation at this year's European Association for the Study of the Liver (EASL) International Liver Congress, due to start on April 22 in Vienna, Austria, compared with last year. Largely, this is because it is hard to improve on the near-100% cure rates seen with the new wave of hepatitis C therapies that were highlighted 12 months ago in London – specifically Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira Pak (paritaprevir/ritonavir/ombitasvir + dasabuvir).

Table

View full table

Topics

Related Companies

Tags:
Austria Clinical Trials
Latest Headlines

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

See All
UsernamePublicRestriction

Register

SC028471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By